Clinically Relevant Doses of Enalapril Mitigate Multiple Organ Radiation Injury

Abstract

Angiotensin-converting enzyme inhibitors (ACEi) are effective mitigators of radiation nephropathy. To date, their experimental use has been in fixed-dose regimens. In clinical use, doses of ACEi and other medication may be escalated to achieve greater benefit. We therefore used a rodent model to test the ACEi enalapril as a mitigator of radiation injury in an escalating-dose regimen. Single-fraction partial-body irradiation (PBI) with one hind limb out of the radiation field was used to model accidental or belligerent radiation exposures. PBI doses of 12.5, 12.75 and 13 Gy were used to establish multi-organ injury. One third of the rats underwent PBI alone, and two thirds of the rats had enalapril started five days after PBI at a dose of 30 mg/l in the drinking water. When there was established azotemic renal injury enalapril was escalated to a 60 mg/l dose in half of the animals and then later to a 120 mg/l dose. Irradiated rats on enalapril had significant mitigation of combined pulmonary and renal morbidity and had significantly less azotemia. Dose escalation of enalapril did not significantly improve outcomes compared to fixed-dose enalapril. The current data support use of the ACEi enalapril at a fixed and clinically usable dose to mitigate radiation injury after partial-body radiation exposure.

Challenges and Benefits of Repurposing Products for Use during a Radiation Public Health Emergency: Lessons Learned from Biological Threats and other Disease Treatments

“…ACE Inhibitors. ACE inhibitors show efficacy in several models of radiation injury, and in multiple organ systems (68). Their use for treating hypertension has generated an enormous safety database, which has extended from pediatric through geriatric patients.…”

Challenges and Benefits of Repurposing Licensed/Approved/Cleared Products for a Radiation Indication

“…Angiotensin converting enzyme (ace) inhibitors. ACE inhibitors are a class of anti-hypertensives with a wellunderstood mechanism of action and an extensive safety database (13) that show efficacy in several models of radiation injury to multiple organ systems (14). For example, lisinopril (15) and enalapril (16) demonstrate a survival benefit even when administered weeks after wholethorax irradiation in rats, and captopril was shown to reduce kidney and lung injuries in patients given a bone marrow transplant after total-body irradiation (17).…”

Pharmabiotics as an Emerging Medication for Metabolic Syndrome and Its Related Diseases

“…For examples, statins are used for lowering cholesterol levels, as well as prevention of coronary heart diseases, heart attack and stroke, in which Rosuvastatin has the highest efficacy in reducing LDL-C than other statins at comparable doses, while atorvastatin may improve hepatic insulin sensitivity that adds a point in treating patients with both T2D and dyslipidemia [ 78 ]. Simvastatin also can potentially increase HDL-C levels, associated with reduced risks of atherosclerosis CVDs [ 63 ]. However, besides beneficial effects on correction dyslipidemia, pharmaceutical drugs have various documented side effects [ 90 ].…”